CSIMarket
 


Dendreon Corp  (DNDN)
Other Ticker:  
 
 

DNDN's Revenue Growth by Quarter and Year

Dendreon's Revenue results by quarter and year




DNDN Revenue (in millions $) FY 2014 FY 2013 FY 2012 FY 2011
IV Quarter December - 74.84 85.49 0.00
III Quarter September 73.12 68.00 77.97 0.00
II Quarter June 82.21 73.32 79.99 0.00
I Quarter March 68.78 67.59 82.07 0.00
FY   224.11 283.75 325.52 0.00



DNDN Revenue third quarter 2014 Y/Y Growth Comment
Dendreon Corp achieved in the third quarter 2014, above Company average Revenue improvement of 7.53% year on year, to $ 73.12 millions.

Looking into third quarter 2014 results within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Revenue growth. While Dendreon Corp' s Revenue increase of 7.53% ranks overall at the positon no. 1678 in the third quarter 2014.




DNDN Revenue ( Y/Y Growth %) 2014
2013 2012 2011
IV Quarter December - -12.46 % - -
III Quarter September 7.53 % -12.79 % - -
II Quarter June 12.12 % -8.34 % - -
I Quarter March 1.76 % -17.64 % - -
FY   - -12.83 % - -

Financial Statements
Dendreon's third quarter 2014 Revenue $ 73.12 millions DNDN's Income Statement
Dendreon's third quarter 2013 Revenue $ 68.00 millions Quarterly DNDN's Income Statement
New: More DNDN's historic Revenue Growth >>


DNDN Revenue (Quarter on Quarter Growth %)

2014
2013 2012 2011
IV Quarter December - 10.06 % 9.64 % -
III Quarter September -11.05 % -7.26 % -2.53 % -
II Quarter June 19.53 % 8.48 % -2.53 % -
I Quarter March -8.1 % -20.94 % - -
FY (Year on Year)   - -12.83 % - -




Revenue third quarter 2014 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #47
Healthcare Sector #208
Overall #1678

Revenue Y/Y Growth Statistics
High Average Low
12.13 % -4.26 % -17.64 %
(Jun 30 2014)   (Mar 31 2013)
Revenue third quarter 2014 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #47
Healthcare Sector #208
Overall #1678
Revenue Y/Y Growth Statistics
High Average Low
12.13 % -4.26 % -17.64 %
(Jun 30 2014)   (Mar 31 2013)

Revenue by Quarter for the Fiscal Years 2011, 2012, 2013, 2014

Dendreon's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
19.53 % -0.47 % -20.94 %
(Jun 30 2014)   (Mar 31 2013)


DNDN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2014 Dendreon Corp reported drop in Revenue sequentially by -11.05% to $ 73.12 millions, from $ 82.21 millions declared in the previous reporting period.

As we evaluate present downturn in the quarter, we should assume, that usually III. Quarter 2014 results occur softer relative to the second quarter, Avery H. Evans, an industry advisor mentioned.

Within Biotechnology & Pharmaceuticals industry 81 other companies have achieved higher Revenue quarter on quarter growth. While Dendreon's Revenue growth quarter on quarter, overall rank is 4125.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #82
Healthcare Sector #471
Overall #4125
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #82
Healthcare Sector #471
Overall #4125
Revenue Q/Q Growth Statistics
High Average Low
19.53 % -0.47 % -20.94 %
(Jun 30 2014)   (Mar 31 2013)


DNDN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2014 Dendreon Corp reported drop in Revenue from the previous quarter by -11.05% to $ 73.12 millions, from $ 82.21 millions declared in the previous quarter.

When you look into recent slump in the III. Quarter 2014, you suppose to presume, that frequently III. Quarter Revenue appear to be sluggish relative to the second quarter

Within Biotechnology & Pharmaceuticals industry 81 other companies have achieved higher Revenue quarter on quarter growth. While Dendreon's Revenue growth quarter on quarter, overall rank is 4125.


Dendreon's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2014)
12 Months Ending
(Jun 30 2014)
12 Months Ending
(Mar 31 2014)
12 Months Ending
(Dec 31 2013)
12 Months Ending
(Sep 30 2013)
Cumulative Revenue 12 Months Ending $ 298.95 $ 293.83 $ 284.93 $ 283.75 $ 294.40
Y / Y Revenue Growth (TTM) 1.54 % -3.46 % -8.4 % -12.84 % -
Year on Year Revenue Growth Overall Ranking # 2282 # 2330 # 2330 # 0 # 0
Seqeuential Revenue Change (TTM) 1.74 % 3.12 % 0.42 % -3.62 % -3.28 %
Seq. Revenue Growth (TTM) Overall Ranking # 2395 # 1793 # 0 # 0 # 2457




Cumulative Revenue growth Comment
With 1.54% annual Revenue growth, Dendreon Corp would report a record annual Revenue improvement if the fiscal year would end on Sep 30 2014.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2282, from total ranking in previous quarter at 2330.

Revenue TTM Q/Q Growth Statistics
High Average Low
1.54 %
-5.79 %
-12.84 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 26
Healthcare Sector # 264
Overall # 2282

Revenue TTM Y/Y Growth Statistics
High Average Low
1.54 %
-5.79 %
-12.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 235
S&P 500 # 2395
Cumulative Revenue growth Comment
With 1.54% annual Revenue growth, Dendreon Corp would report a record annual Revenue improvement if the fiscal year would end on Sep 30 2014.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2282, from total ranking in previous quarter at 2330.

Revenue TTM Q/Q Growth Statistics
High Average Low
1.54 %
-5.79 %
-12.84 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 26
Healthcare Sector # 264
Overall # 2282

Revenue TTM Y/Y Growth Statistics
High Average Low
1.54 %
-5.79 %
-12.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 235
S&P 500 # 2395




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DNDN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for DNDN's Competitors
Revenue Growth for Dendreon's Suppliers
Revenue Growth for DNDN's Customers

You may also want to know
DNDN's Annual Growth Rates DNDN's Profitability Ratios DNDN's Asset Turnover Ratio DNDN's Dividend Growth
DNDN's Roe DNDN's Valuation Ratios DNDN's Financial Strength Ratios DNDN's Dividend Payout Ratio
DNDN's Roa DNDN's Inventory Turnover Ratio DNDN's Growth Rates DNDN's Dividend Comparisons



Companies with similar Revenue improvement for the quarter ending Sep 30 2014 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2014
Pediatrix Medical Group Inc 12.94%$ 12.939 millions
Orasure Technologies Inc12.87%$ 12.865 millions
Celldex Therapeutics inc 12.35%$ 12.347 millions
Nuvasive Inc12.27%$ 12.274 millions
Charles River Laboratories International inc 12.13%$ 12.131 millions
Sonida Senior Living Inc 11.93%$ 11.934 millions
Star Equity Holdings Inc 11.83%$ 11.826 millions
Merit Medical Systems Inc11.80%$ 11.803 millions
Henry Schein Inc11.70%$ 11.698 millions
Endologix Inc11.70%$ 11.696 millions
Luminex Corporation11.63%$ 11.627 millions
National Healthcare Corp11.47%$ 11.468 millions
Tivity Health Inc 11.43%$ 11.428 millions
Remedent Inc 11.34%$ 11.339 millions
Cutera Inc 11.28%$ 11.279 millions
Baxter International Inc 11.21%$ 11.208 millions
Universal Health Services Inc 11.09%$ 11.087 millions
Caladrius Biosciences Inc 11.08%$ 11.084 millions
Stryker Corp11.06%$ 11.065 millions
Teleflex Incorporated10.48%$ 10.483 millions
Intuitive Surgical Inc 10.24%$ 10.240 millions
Lifeloc Technologies Inc 10.11%$ 10.112 millions
Globus Medical Inc 9.89%$ 9.889 millions
Zoetis Inc 9.70%$ 9.701 millions
Masimo Corp9.64%$ 9.640 millions
Bard C R Inc9.50%$ 9.499 millions
Cyteir Therapeutics Inc 9.25%$ 9.248 millions
Psychemedics Corp9.20%$ 9.197 millions
Omeros Corp9.18%$ 9.184 millions
United Therapeutics Corporation9.17%$ 9.174 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com